Anti-RCAS1 (Human) mAb
| Code | Size | Price |
|---|
| MBL-D060-3 | 100 ul | £350.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgM κ
Antibody Clonality: Monoclonal
Antibody Clone: 22-1-1
Regulatory Status: RUO
Target Species: Human
Applications:
- Flow Cytometry
- Immunohistochemistry (IHC)
Shipping:
4°C
Storage:
-20°C
Documents
Further Information
Applications:
IP - Reference 1-3 and 5-7 FCM - 1-5 ug/mL (final concentration) IHC - 1-5 ug/mL
Background:
RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) is a novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. The predicted amino acid sequence of RCAS1 (213 aa) possesses an N-terminal transmembrane region and a coiled-coil structure in the C-terminal portion, indicating that RCAS1 is a type II membrane protein able to form oligomers through the coiled-coil structure. RCAS1 revealed different expression pattern from the known tumor associated antigens such as, YH206, GA733, CA125, CEA and sialyl Lewis molecules in human tumor cell lines. Recent study indicated RCAS1 acts as a ligand for a putative receptor present on various human cells including T, B and NK cells. RCAS1 inhibited the in vitro growth of receptor-expressing cells and induced apoptosis. It was suggested that tumor cells might evade immune surveillance by expression of RCAS1.
Concentration:
1 mg/mL
Formulation:
100 ugIgMin 100uL volume of PBS containing 50% glycerol and 0.5M NaCl, pH 7.2. Nopreservative is contained.
Gene IDs:
Human: 9166 Mouse: 55960
Immunogen Translated:
Jugular gland of human uterine cancer cells
Reactivity:
This antibody reacts with
RCAS1 on
Flow cytometry and Immunohistochemistry.
Shelf Life:
1 year
Source:
This antibody was purified from
hybridoma
(clone 22
-
1
-
1) supernatant
using protein
L
agarose
. This
hybridoma
was established
by fusion of mouse myeloma
cell
x63.
Ag8.653 with Balb/c mouse splen
ocyte immunized
with
human
uterine cervical adenocarcinoma cells.
Target:
RCAS1
References
1) Giaginis, C., et al., Dis Markers. 35, 213-219 (2013) [IHC]
2) Giaginis,C., et al., Med Sci Monit. 18, BR123-129 (2012)[IHC]
3) Theocharis,S., et al., Med Sci Monit. 17, BR228-234(2011) [IHC]
4) Wolf, J., et al., FASEB J. 24, 4000-4019 (2010) [FCM]
5) Oshikiri, T., et al., Clin. Cancer Res. 12, 411-416 (2006)[IHC]
6) Reimer, R. A., et al., BMC Cancer 5, 47-59 (2005) [IHC]
7) Leelawat, K., et al., J. Clin. Pathol. 56, 764-768 (2003) [IHC]
8) Suzuoki, M., et al., Ann. Surg. Oncol. 9, 388-393 (2002)
9) Izumi, M., et al., Cancer 92, 446-451 (2001)
10) Matsushima, T., et al., Blood 98, 313-321 (2001)
11) Nakashima, M., et al., Nat. Med. 5, 938-942 (1999)
12) Sonoda, K., at al., Cancer 77, 1501-1509 (1996)